Author

Z. R. Simmons

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

C. W. Vander Kooi· 3 shared M. S. Gentry· 3 shared S. Li· 2 shared A. Kuchtova· 1 shared B. L. Hodges· 1 shared D. Armstrong· 1 shared G. L. Austin· 1 shared J. E. Klier· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

C. W. Vander Kooi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistrybioRxivMar 26, 2021

An empirical pipeline for personalized diagnosis of Lafora disease mutations

M. K. Brewer, M. Machio-Castello, R. Viana…·M. S. Gentry

This paper develops an empirical pipeline to classify EPM2A mutations in Lafora disease by analyzing their functional impact in vitro, linking specific mutations to clinical outcomes.

DOI 10.1016/j.isci.2021.103276

humanwhole-exome sequencing

𝕏 PostBluesky

BiochemistrybioRxivJan 20, 2021

Generation and characterization of a laforin nanobody inhibitor

Z. R. Simmons, S. Sharma, J. Wayne…·M. S. Gentry

This study generates and characterizes laforin nanobodies to inhibit its catalytic activity and better understand its role in Lafora disease.

DOI 10.1016/j.clinbiochem.2021.03.017

humanexperimental assay

𝕏 PostBluesky

BioengineeringbioRxivJun 14, 2019

Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease

G. L. Austin, Z. R. Simmons, J. E. Klier…·M. S. Gentry

This study evaluates the cerebral delivery and biodistribution of VAL-0417, an antibody-enzyme fusion for Lafora disease, showing intracerebroventricular administration is most effective.

DOI 10.1021/acs.molpharmaceut.9b00396

mouseprotein structure

𝕏 PostBluesky